Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Standardized Chemical Allergen [EPC]
Ethylene Dibromide (1,2-Dibromoethane) is a standardized chemical allergen used primarily in diagnostic patch testing to identify contact dermatitis. It is classified as a potent sensitizer and industrial chemical with significant clinical monitoring requirements.
Name
Ethylene Dibromide
Raw Name
ETHYLENE DIBROMIDE
Category
Standardized Chemical Allergen [EPC]
Drug Count
3
Variant Count
3
Last Verified
February 17, 2026
About Ethylene Dibromide
Ethylene Dibromide (1,2-Dibromoethane) is a standardized chemical allergen used primarily in diagnostic patch testing to identify contact dermatitis. It is classified as a potent sensitizer and industrial chemical with significant clinical monitoring requirements.
Detailed information about Ethylene Dibromide
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Ethylene Dibromide.
Ethylene Dibromide, chemically known as 1,2-dibromoethane (EDB), is a halogenated hydrocarbon that serves a dual role in modern history: formerly as a heavy-duty industrial fumigant and currently as a Standardized Chemical Allergen [EPC]. In a clinical context, Ethylene Dibromide belongs to a class of diagnostic substances used by dermatologists and allergists to identify specific cell-mediated (Type IV) hypersensitivity reactions. While it is no longer used as a therapeutic medication for treating diseases, its presence in diagnostic kits is critical for patients suffering from chronic contact dermatitis (skin inflammation caused by contact with external substances).
Historically, Ethylene Dibromide was widely utilized as a soil and grain fumigant and as an additive in leaded gasoline to prevent lead deposits in engines. However, due to its significant toxicity and carcinogenic potential, the U.S. Environmental Protection Agency (EPA) banned most of its agricultural uses in 1984. Today, its clinical relevance is almost exclusively limited to its role as a diagnostic tool. When used as a standardized allergen, a minute, controlled concentration of the chemical is applied to the skin to determine if a patient has developed an immunological memory to the substance, which may be the hidden cause of their skin rashes or systemic allergic symptoms.
According to the FDA's Established Pharmacologic Class (EPC) system, Ethylene Dibromide is categorized as a Standardized Chemical Allergen. Interestingly, it is also associated with the Copper-containing Intrauterine Device [EPC] classification in certain regulatory databases, likely due to its historical use in the manufacturing or testing phases of specific medical devices. Patients should understand that Ethylene Dibromide is not a 'treatment' but a 'test'—a distinction that is vital for managing expectations during the diagnostic process.
As a diagnostic allergen, Ethylene Dibromide works through the mechanism of Type IV Hypersensitivity, also known as delayed-type hypersensitivity. Unlike immediate allergic reactions (like hay fever or anaphylaxis), Type IV reactions are mediated by T-lymphocytes (a type of white blood cell) rather than antibodies.
At the molecular level, Ethylene Dibromide acts as a hapten. A hapten is a small molecule that is not immunogenic (capable of producing an immune response) on its own. However, once it penetrates the stratum corneum (the outermost layer of the skin), it binds covalently to endogenous skin proteins. This chemical-protein complex is then recognized by Langerhans cells (specialized immune cells in the skin). These cells process the complex and migrate to local lymph nodes, where they 'present' the allergen to T-cells. If the patient has been previously sensitized to Ethylene Dibromide, these T-cells will proliferate and migrate back to the site of contact, releasing pro-inflammatory cytokines (chemical messengers) that cause the visible redness, swelling, and itching characteristic of a positive patch test.
While Ethylene Dibromide is applied topically during clinical testing, its pharmacokinetic profile is well-documented due to its industrial history and the risk of systemic absorption.
The FDA-approved clinical use of Ethylene Dibromide is restricted to:
Off-label uses are virtually non-existent due to the high toxicity of the compound. It is never used for therapeutic purposes.
Ethylene Dibromide is not available in standard consumer dosage forms like tablets or injections. It is found in:
> Important: Only your healthcare provider can determine if Ethylene Dibromide is right for your specific condition. The use of this substance must be strictly controlled by a medical professional to avoid severe chemical burns or systemic toxicity.
In the context of diagnostic patch testing, the 'dosage' of Ethylene Dibromide is not measured in milligrams per kilogram, but rather in the concentration and volume applied to a specific area of the skin.
Ethylene Dibromide is generally not recommended for use in children. Pediatric contact dermatitis is usually tested with a 'pediatric series' of allergens that are more common in children's environments (such as nickel, fragrances, or preservatives). If a healthcare provider deems it absolutely necessary to test a child for EDB sensitivity, the concentration may be further diluted to reduce the risk of an irritant reaction or systemic absorption. However, there is no standardized FDA-approved pediatric dosage for this chemical.
While the amount of Ethylene Dibromide absorbed during a patch test is minimal, patients with severe renal (kidney) impairment should be monitored closely. The metabolites of EDB are excreted renally, and a reduced glomerular filtration rate (GFR) could theoretically slow the clearance of any absorbed fraction.
Because the liver is the primary site of EDB metabolism (via CYP2E1 and GST), patients with hepatic (liver) impairment may have an altered metabolic response. However, no specific dose adjustments are required for topical patch testing, as systemic levels remain extremely low.
Elderly patients often have thinner skin (atrophy), which can increase the rate of absorption and the risk of an irritant (non-allergic) reaction. Healthcare providers may choose to read the test results more frequently or use a lower concentration in patients over the age of 65.
Ethylene Dibromide is never 'taken' by the patient. It is always applied by a healthcare professional. The process typically follows these steps:
If a patch falls off before the 48-hour mark, the test is considered compromised. The patient should contact their dermatologist immediately. Do not attempt to re-apply the patch with household tape, as this can interfere with the results. The test may need to be restarted at a later date.
In a clinical setting, an 'overdose' would involve the application of too high a concentration or leaving the patch on for too long. Signs of a localized overdose include:
In case of suspected systemic exposure or a severe skin reaction, the patch should be removed immediately, the area washed with mild soap and water, and emergency medical services should be contacted.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose or remove the diagnostic patches without medical guidance.
Because Ethylene Dibromide is a potent skin irritant as well as an allergen, side effects at the site of application are common. These include:
These symptoms typically resolve within 1 to 2 weeks after the patches are removed.
While extremely rare in diagnostic testing, systemic absorption of Ethylene Dibromide is a medical emergency.
> Warning: Stop taking Ethylene Dibromide (remove the patch) and call your doctor immediately if you experience any of these:
The primary concern with long-term or repeated exposure to Ethylene Dibromide is its status as a Group 2A Carcinogen (probably carcinogenic to humans) according to the IARC. While a single diagnostic patch test is not believed to significantly increase cancer risk, chronic occupational exposure is linked to:
There is no standard FDA 'Black Box Warning' for Ethylene Dibromide specifically as a diagnostic allergen because it is not a systemic drug. However, the EPA and OSHA provide 'Danger' labels for the chemical in industrial settings, highlighting its status as a potent carcinogen and respiratory toxin. Clinicians must handle the concentrated chemical with extreme caution, using gloves and adequate ventilation.
Report any unusual symptoms to your healthcare provider. If you notice signs of infection (fever, yellow drainage) at the test site, contact your dermatologist immediately.
Ethylene Dibromide is a hazardous substance that requires professional handling. It should never be used for self-testing. Patients with a history of severe reactions to halogenated hydrocarbons (like certain refrigerants or solvents) must inform their doctor before undergoing a patch test with this substance.
No FDA black box warnings for Ethylene Dibromide in its capacity as a standardized allergen. However, it is regulated under strict environmental and occupational safety guidelines due to its high toxicity profile in vapor form.
For a standard diagnostic test, no blood work is typically required. However, if a patient is accidentally exposed to high levels of Ethylene Dibromide, the following should be monitored:
A diagnostic patch test does not typically affect a patient's ability to drive or operate machinery. However, if the patient experiences significant discomfort or a rare systemic reaction (like dizziness), they should avoid these activities until the symptoms resolve.
There are no known direct interactions between alcohol and the Ethylene Dibromide patch test. However, alcohol can cause vasodilation (widening of blood vessels), which might increase skin redness and itching, potentially complicating the interpretation of the test results. It is best to avoid excessive alcohol during the 96-hour testing window.
In the context of a patch test, 'discontinuation' means removing the patch early. This should only be done if the patient experiences severe pain, burning, or systemic symptoms. Tapering is not required as EDB is not a chronic systemic medication.
> Important: Discuss all your medical conditions with your healthcare provider before starting Ethylene Dibromide testing. Ensure your doctor knows if you are taking any immunosuppressant medications.
Ethylene Dibromide testing should not be performed while a patient is taking high doses of systemic Corticosteroids (e.g., Prednisone > 10-20mg daily).
There are no specific food-drug interactions for Ethylene Dibromide. However, a diet high in anti-inflammatory supplements (like high-dose Omega-3 or Curcumin) might theoretically reduce the intensity of a positive skin reaction, though this is not clinically standardized.
Ethylene Dibromide does not typically interfere with standard blood or urine lab tests. However, its presence in the body can be detected through specialized gas chromatography-mass spectrometry (GC-MS) if systemic poisoning is suspected.
For each major interaction, the primary concern is the diagnostic accuracy of the test. Because EDB is not used as a therapeutic drug, the goal of managing interactions is to ensure the immune system is 'primed' enough to react if an allergy exists, but not so reactive that it produces a false positive.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, especially any creams or ointments you use on your skin.
Ethylene Dibromide must NEVER be used in the following situations:
Conditions requiring careful risk-benefit analysis include:
Patients who react to Ethylene Dibromide may also show cross-sensitivity to other halogenated compounds, such as:
Your doctor will evaluate these cross-reactivities when interpreting your results to provide a comprehensive list of substances you should avoid in your daily life.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Ethylene Dibromide patch testing.
Ethylene Dibromide is classified by the IARC as a probable human carcinogen and has shown teratogenic (birth defect-causing) and embryotoxic effects in animal studies at high doses.
It is unknown if Ethylene Dibromide or its metabolites pass into human breast milk. However, given the molecule's lipophilic nature, it is possible. Because the amount absorbed during a patch test is extremely small, the risk to a nursing infant is likely low, but a risk-benefit discussion with a pediatrician is required. To be safe, some clinicians suggest 'pumping and discarding' for 24 hours after the test patches are removed.
Safety and effectiveness in pediatric patients have not been established. Children have a higher surface-area-to-body-mass ratio, which increases the risk of systemic absorption. Furthermore, the immune system of a child is still developing, and the risk of 'iatrogenic sensitization' (causing a new allergy) is a concern. Pediatric use is generally restricted to cases where an occupational or specific environmental exposure is strongly suspected.
In patients over 65, several factors must be considered:
No specific dose adjustment is needed for the topical patch, but patients with Stage 4 or 5 Chronic Kidney Disease should be monitored for any unusual systemic symptoms. Dialysis does not remove DNA adducts but may remove the parent compound.
In patients with severe liver disease (Child-Pugh Class C), the metabolism of EDB via the GST and CYP2E1 pathways may be impaired. While topical testing is generally safe, clinicians should be aware that the 'toxification' of EDB happens in the liver, and altered enzyme levels could theoretically change the systemic risk profile.
> Important: Special populations require individualized medical assessment by a specialist in dermatology or allergy and immunology.
Ethylene Dibromide (1,2-dibromoethane) acts as a pro-hapten. Once it enters the skin, it undergoes metabolic activation (likely via cutaneous enzymes) to become a reactive electrophile. This electrophile then forms a covalent bond with the amino acid residues (like lysine or cysteine) of skin proteins. This 'haptenated' protein is the actual antigen that triggers the T-cell mediated immune response.
In a toxicological context, EDB's mechanism involves the formation of S-[2-(N7-guanyl)ethyl]glutathione DNA adducts. This occurs when the chemical is conjugated with glutathione; the resulting sulfur mustard-like intermediate binds to DNA, specifically at the guanine bases. This is the primary mechanism behind its mutagenicity and carcinogenicity.
| Parameter | Value |
|---|---|
| Bioavailability | <1% (Topical Patch); ~100% (Inhalation) |
| Protein Binding | Very High (Covalent) |
| Half-life | ~12-24 hours (Systemic) |
| Tmax | 1-2 hours (Topical absorption peak) |
| Metabolism | Hepatic (CYP2E1 and GST) |
| Excretion | Renal (Metabolites) |
Ethylene Dibromide is classified as a Standardized Chemical Allergen. It is related to other halogenated hydrocarbons but is unique in its specific potency as a sensitizer. It is often grouped in 'Industrial Series' or 'Plastic & Glue Series' in diagnostic allergy kits.
Common questions about Ethylene Dibromide
Ethylene Dibromide is primarily used as a diagnostic tool called a patch test to identify if a person has an allergy to certain industrial chemicals. In the past, it was used as a pesticide and gasoline additive, but these uses were largely banned due to safety concerns. In a clinical setting, it helps dermatologists determine the cause of chronic skin rashes or contact dermatitis. It is not used to treat any medical condition but rather to diagnose an underlying allergy. The test involves applying a tiny amount of the chemical to the skin for 48 hours under medical supervision.
The most common side effects occur at the site of the patch test and include redness, itching, and mild swelling. These symptoms are actually what the doctor looks for, as they indicate a positive allergic reaction. Some patients may also develop small blisters or a temporary darkening of the skin at the test site. These localized reactions usually appear 2 to 4 days after the test begins and can last for a week or two. Because the amount used is so small, systemic side effects like nausea or dizziness are extremely rare.
While there is no direct chemical interaction between alcohol and the Ethylene Dibromide used in a patch test, it is generally advised to limit alcohol consumption during the testing period. Alcohol can cause your blood vessels to dilate, which might make the skin on your back more flushed or itchy. This can make it difficult for your doctor to accurately read the test results. Furthermore, excessive alcohol can affect your immune system's inflammatory response. For the most accurate diagnosis, it is best to stay hydrated with water and avoid alcohol until the final reading is completed.
Ethylene Dibromide is generally avoided during pregnancy because it is known to be a potent chemical with mutagenic potential in laboratory studies. While the risk from a single, small diagnostic patch is likely very low, most doctors prefer to wait until after the baby is born to perform elective allergy testing. Animal studies have shown that high levels of this chemical can be toxic to a developing fetus. If you are pregnant or planning to become pregnant, you must inform your dermatologist before undergoing any chemical patch testing. Safety is the priority, and testing can almost always be delayed.
Ethylene Dibromide works through a delayed immune response, meaning it does not show results immediately. The patch must typically stay on the skin for 48 hours to allow the chemical to penetrate and the immune cells to react. Even after the patch is removed, the reaction may continue to develop over the next several days. Doctors usually perform a final 'reading' of the test 3 to 4 days (72 to 96 hours) after the initial application. If you have a very strong allergy, you might feel itching within the first 24 hours, but the official result requires the full waiting period.
In the context of a diagnostic test, 'stopping' means removing the patch from your skin. You should not do this unless you experience severe pain, a burning sensation, or signs of a serious allergic reaction like trouble breathing. If you remove the patch early without a medical reason, the test will be invalid and will likely need to be repeated later. Unlike daily medications, there are no withdrawal symptoms from stopping a patch test. Always call your doctor's office before removing the patches to discuss your symptoms and get professional guidance.
Because Ethylene Dibromide is applied by a healthcare professional in a clinic, you cannot 'miss a dose' in the traditional sense. However, if the patch falls off your back prematurely, this is considered a failed test. Do not try to tape it back on yourself, as this can contaminate the area or change the concentration of the chemical. Contact your dermatologist immediately to see if they can re-apply the patch or if you need to reschedule the test. Keeping the area dry and avoiding heavy exercise will help prevent the patch from falling off.
No, Ethylene Dibromide used in diagnostic patch testing does not cause weight gain. Weight gain is typically a side effect of systemic medications that affect metabolism or appetite, such as oral steroids or certain antidepressants. Because the amount of Ethylene Dibromide used in a skin test is microscopic and applied only once, it does not enter the system in high enough quantities to affect your weight or metabolic rate. If you experience sudden weight changes, you should discuss them with your primary care physician to find the actual cause.
Ethylene Dibromide can be used while you are taking most medications, but there are important exceptions. Systemic immunosuppressants, such as oral prednisone or chemotherapy, can suppress your immune system's ability to react to the test, leading to a false negative. You should also avoid using steroid creams on the area of your back where the test will be performed. Always provide your doctor with a full list of your current medications, including over-the-counter supplements, to ensure they don't interfere with the accuracy of your allergy diagnosis.
Ethylene Dibromide is not a 'brand name' drug; it is a basic chemical compound used in various standardized allergen kits. These kits are manufactured by specialized companies like Chemotechnique Diagnostics or SmartPractice. While there are different brands of patch test systems, the Ethylene Dibromide chemical itself is standardized across the industry. It is not something you can buy at a pharmacy with a prescription; it is only available through specialized medical providers who perform comprehensive allergy testing.